Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 6/20 | 0.60 |
| ▸ | SLC6A13 | Q9NSD5 | 6/20 | 0.60 |
| ▸ | SLC6A11 | P48066 | 5/20 | 0.60 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 5/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.32 |
| ▸ | PEPD | P12955 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7739792 | 1.00 | SLC6A12 (0.60) | SLC6A12SLC6A13SLC6A11GABRA5GABRB2 | |
| SCHEMBL7740219 | 1.00 | SLC6A12 (0.60) | SLC6A12SLC6A13SLC6A11GABRA5GABRB2 | |
| SCHEMBL7739796 | 1.00 | SLC6A12 (0.60) | SLC6A12SLC6A13SLC6A11GABRA5GABRB2 | |
| SCHEMBL30445198 | 1.00 | SLC6A12 (0.60) | SLC6A12SLC6A13SLC6A11GABRA5GABRB2 | |
| SCHEMBL7740218 | 1.00 | SLC6A12 (0.60) | SLC6A12SLC6A13SLC6A11GABRA5GABRB2 | |
| SCHEMBL7410374 | 0.95 | SLC6A12 (0.60) | SLC6A12SLC6A13SLC6A11GABRA5GABRB2 | |
| SCHEMBL3742078 | 0.95 | SLC6A12 (0.60) | SLC6A12SLC6A13SLC6A11GABRA5GABRB2 | |
| SCHEMBL28777375 | 0.86 | — | — | |
| SCHEMBL11051978 | 0.83 | SLC6A12 (0.52) | SLC6A12SLC6A13SLC6A11GABRA5GABRB2 | |
| SCHEMBL7814549 | 0.82 | SLC6A12 (0.38) | SLC6A12SLC6A13SLC6A11THRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612624-B2 | Light-inducible CRISPR/Cas9 system for genome editing | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250353927-A1 | SERINE PROTEASE INHIBITOR KAZAL (SPIK) COMPOSITIONS AND METHODS | IMCARE BIOTECH LLC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12404312-B2 | Engineered VEGF variants for retinal neuroprotection, promotion of axon growth and axon regeneration | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250250562-A1 | TAT-INDUCED CRISPR/ENDONUCLEASE-BASED GENE EDITING | UNIV TEMPLE (US) | 2025-08-07 | — | — | US | disclosed |
| US-12377162-B2 | Anti-serine protease inhibitor kazal (SPIK) antibodies, immunoconjugates, and methods of use | IMCARE BIOTECH, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| US-12357704-B2 | Tailored hypoimmune nanovesicular delivery systems for cancer tumors | Malcolm, Thomas (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250135032-A1 | CRISPR METHODS FOR CORRECTING BAG3 GENE MUTATIONS IN VIVO | UNIV TEMPLE (US) | 2025-05-01 | — | — | US | disclosed |
| EP-4522193-A2 | METHODS FOR TREATING AND/OR PREVENTING UNDESIRABLE SEQULAE OF NASAL TURBINOPLASTY OR FUNCTIONAL ENDOSCOPIC SINUS SURGERY | 3-D Matrix Ltd. (JP) | 2025-03-19 | — | — | EP | disclosed |
| US-12251429-B2 | Methods and compositions for RNA-guided treatment of HIV infection | Temple University—Of the Commonwealth System of Higher Education (US) | 2025-03-18 | — | — | US | disclosed |
| US-20250082778-A1 | RNA GUIDED ERADICATION OF HUMAN JC VIRUS AND OTHER POLYOMAVIRUSES | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2025-03-13 | — | — | US | disclosed |
| WO-2006042035-A2 | METHOD OF MONITORING ANTI-TUMOR ACTIVITY OF AN HDAC INHIBITOR | PHARMACYCLICS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20050131018-A1 | Acetylene derivatives as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-16 | — | — | US | disclosed |
| WO-2005019174-A1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-6420427-B1 | PREVENTION AND/OR TREATMENT OF RHEUMATOID DISEASES, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS, INTERSTITIAL NEPHRITIS, ARTERIOSCLEROSIS, PULMONARY EMPHYSEMA, CIRRHOSIS, CORNEA INJURY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| CN-1282319-A | Aminobutanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 2001-01-31 | — | — | CN | disclosed |
| EP-1024134-A1 | AMINOBUTANOIC ACID DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-08-02 | — | — | EP | disclosed |
| US-5840704-A | INSECTICIDES, MITICIDES, ANTHELMINTICS | PFIZER INC. (US) | 1998-11-24 | — | — | US | disclosed |
| US-5451511-A | Biosynthesis, avermectins | PFIZER INC. (US) | 1995-09-19 | — | — | US | disclosed |
| US-5089480-A | ANTIPARASITIC AGENTS | PFIZER INC. (US) | 1992-02-18 | — | — | US | disclosed |
| EP-0214731-A2 | Antiparasitic avermectin and milbemycin derivatives and process for their preparation | Pfizer Limited (GB) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612624-B2 | Light-inducible CRISPR/Cas9 system for genome editing | RNMT, AMPD2, NT5C2 | SLC6A12 1547/4885SLC6A13 4228/4885SLC6A11 4116/4885 |
| US-20050131018-A1 | Acetylene derivatives as inhibitors of histone deacetylase | HDAC1, HDAC10, HDAC2 | SLC6A12 4727/4885SLC6A13 4791/4885SLC6A11 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.